title: [Human monocyte-derived multinucleated giant cells].
abstract: Multinucleated giant cells (MGC) are characteristic cells in granulomatous disorders such as sarcoidosis and leprosy. There are two types of MGC; foreign body-type and Langhans-type cells. The exact mechanisms of the formation and the functional significance of MGC are not determined, although their morphological features are well understood. MGC are also formed in vitro from peripheral blood mononuclear cells by stimulation with cytokines and lectins. Particularly IFN-gamma is considered to play a pivotal role in monocyte fusion. IL-3, IL-4, IL-13, and GM-CSF are other reported cytokines involved in MGC formation. In addition to such inflammatory mediators, a factor derived from the pathogens of granulomatous disorders may be necessary for MGC formation. Muramyl dipeptide, a peptidoglycan portion of bacterial cell walls, is one of the candidates and can preferentially induce Langhans-type cells in in vitro MGC formation system. Although the exact mechanisms of in vitro MGC formation remains unknown, cell surface molecules such as P2X7 receptor, integrins, CD98, and macrophage fusion protein are considered to be involved in fusion process. Monocytes of sarcoidosis patients expressed higher levels of P2X7 and had a higher ability to induce MGC than those of healthy controls. Effective agents for sarcoidosis such as tranilast, alloprinol, and captopril inhibited in vitro MGC formation, suggesting their therapeutic effects through the direct effects on monocytes. Thus, an in vitro MGC formation model would be a useful tool to understand the relevance of MGC in granulomatous disorders.
authors.affiliation: Department of Dermatology, Kansai Medical University, Moriguchi, Osaka, Japan. hokamoto@takii.kmu.ac.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okamoto
authors.forename: Kana
authors.initials: K
authors.lastname: Mizuno
authors.forename: Takeshi
authors.initials: T
authors.lastname: Horio
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine; D000818:Animals; D002459:Cell Fusion; D016207:Cytokines / Q000502:physiology; D027261:Fusion Regulatory Protein-1 / Q000502:physiology; D015726:Giant Cells / Q000473:pathology*; D006105:Granulomatous Disease, Chronic / Q000473:pathology*; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D016023:Integrins / Q000502:physiology; D007963:Leukocytes, Mononuclear / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D009000:Monocytes / Q000473:pathology*; D018048:Receptors, Purinergic P2 / Q000502:physiology; D058486:Receptors, Purinergic P2X7
chemical_list: D016207:Cytokines; D027261:Fusion Regulatory Protein-1; D018836:Inflammation Mediators; D016023:Integrins; C546468:P2RX7 protein, human; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; D000119:Acetylmuramyl-Alanyl-Isoglutamine